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OBJECTIVE — Individuals with diabetes are at higher risk for depression than the general
population. Although depression can be treated with antidepressant medications, patients with
diabetes and comorbid depression often go untreated. The goal of this study was to examine
racial disparities in the treatment of depression with antidepressant medication in the south-
eastern U.S.
RESEARCH DESIGN AND METHODS — Cross-sectional data were collected at base-
line from 69,068 participants (71% African American, 60% female, and 82% with incomes
$25,000) recruited from community health centers and enrolled in the Southern Cohort
Community Study (SCCS). The SCCS is a prospective epidemiological cohort study designed to
explore causes of health disparities in adults aged 40–79 years. Binary logistic regression was
used to identify factors associated with antidepressant use among those with diabetes (n 
14,279).
RESULTS — Individualswithdiagnoseddiabetes(14,279)wereclassiﬁedwithnodepressive
symptoms (54.7%), or with mild (24.2%), moderate (12.8%), or severe depressive symptoms
(8.3%). After controlling for sex, age, insurance, income, education, BMI, smoking status,
alcohol consumption, and level of depression, African Americans with diabetes were much less
likely to report taking antidepressant medication than whites (adjusted odds ratio 0.32 [95% CI
0.29–0.35], P  0.0001).
CONCLUSIONS — Antidepressant use is much less common among African Americans
than among whites with diabetes. Reasons for racial disparities in treatment of depressive symp-
tomsareunclearbutmayincludeacombinationofdifferentialdiagnosisandtreatmentbyhealth
professionals as well as cultural differences in seeking help for emotional distress.
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D
epression is one of the most com-
mon psychiatric disorders. Almost
one of every ﬁve people in the U.S.
will experience a major depressive epi-
sode during their lifetime. Individuals
with diabetes are as much as twice as
likely as those without diabetes to experi-
ence depression (1). Despite its relevance
to the course of diabetes, it is estimated
that depression is recognized and treated
in 25–50% of individuals with diabetes
who are depressed (2). Women are more
likely to be recognized (1), as are those
with panic attacks, frequent primary care
visits, and poorer health (3). Less is
known about the identiﬁcation of depres-
sion in speciﬁc racial and ethnic groups
with diabetes. Variation in the identiﬁca-
tion of depression might explain noted
racial/ethnic disparities in diabetes out-
comes (i.e., why, on average, African
Americanshaveworsecontroloftheirdis-
ease, and experience more diabetes-
related complications and mortality than
whites do).
In diabetes, comorbid depression has
been associated with difﬁculty perform-
ingdiabetesself-carebehaviors(4),worse
glycemic control (5–7), and adverse
healthoutcomes(8).Inlargecohortstud-
ies, comorbid depression was associated
witha36–38%increasedriskinall-cause
mortality compared with that in individ-
uals with diabetes alone (9); in a separate
cohortstudy,itwasassociatedwitha1.3-
fold increase risk in all-cause mortality
(10). The human toll of diabetes and de-
pression translates into a 50% increase in
health care costs compared to the cost of
treating diabetes alone (8).
The successful treatment of depres-
sion may reduce health care costs (11) by
improvingglycemiccontrol,overallfunc-
tioning, and the quality of life of individ-
uals with diabetes (2). Studies show that
psychotherapeutic and pharmacological
treatment is effective for patients with di-
abetes and comorbid depression (12).
Suchtreatmenthasbeenassociatedwitha
reduction in depressive symptoms (6)
and improvements in glycemic control
(5–7) and may ultimately reduce the risk
of adverse health outcomes associated
with depression and diabetes.
In an effort to reduce and eventually
eliminate well-documented racial/ethnic
disparities in diabetes outcomes, it is im-
portant to know whether certain racial/
ethnic groups with diabetes and
comorbid depression are differentially
identiﬁed and/or treated for depression.
In this study, we investigated racial
variation in self-reported 1) physician-
diagnosed diabetes, 2) the presence and
severity of depressive symptoms, and 3)
the treatment for depression in a large
cohort of low-income adults with
diabetes.
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METHODS— TheSouthernCommu-
nityCohortStudy(SCCS)isaprospective
cohort study designed to identify causes
of health disparities between African
Americans and whites in the incidence
and mortality rates of several cancers and
other chronic diseases (13). The study
was approved by the institutional review
boards at Vanderbilt University and Me-
harry Medical College. Participants were
enrolled in person at Community Health
Centers (CHCs) in the states of Alabama,
Arkansas, Florida, Georgia, Kentucky,
Louisiana, Mississippi, North Carolina,
South Carolina, Tennessee, Virginia, and
West Virginia. Participants were enrolled
by approaching people entering the
CHCs(patientsandindividualsaccompa-
nying patients) and screening them for
eligibility and interest in study participa-
tion. Participants were required to be be-
tween the ages of 40 and 79, to speak
English, and to not have been treated for
cancer (excluding nonmelanoma skin
cancer)withinthepastyear.Afterprovid-
ing informed consent, trained interview-
ers collected baseline data using a
computer-assisted personal interview.
The baseline interview contained ques-
tions on demographic information, med-
icalhistory,familyhistory,environmental
and occupational exposures, diet, physi-
cal activity, and psychosocial variables.
Measures
Depression. Depressivesymptomswere
assessed using a 10-item version of the
Centers for Epidemiological Studies De-
pression (CES-D) scale, a valid and reli-
able measure of the presence and severity
of depressive symptoms (14). Cutoffs of
10,15,and20deﬁnemild,moderate,and
severe levels of depressive symptoms
(14). The CES-D has demonstrated mea-
surement equivalency in samples with
differential characteristics including race
and sex (15).
Antidepressant use. Participants were
asked if they were taking any antidepres-
sant medication or antianxiety medica-
tion and then asked for the name(s) of all
medications of this type being taken.
Selection of subjects for analysis
The initial dataset consisted of 69,068 in-
dividuals.Individualswithmissingvalues
for BMI (n  1,575), education (n  45),
income (n  736), smoking status (n 
100), marital status (n  8), insurance
(n336),andalcoholconsumption(n
310) and those who were aged 40 years
(n2),hadadepressivesymptomsscore
(n  99), did not answer the question
about having diabetes or hypertension
(n  53), or did not answer the question
about using antidepressants (n  37)
were excluded, resulting in 65,767 indi-
viduals selected for analysis. Participants
with diabetes were identiﬁed using the
question, “Has a doctor ever told you that
you have diabetes?” Participants who an-
swered “yes” to this question were se-
lected for analysis, consisting of 21.7% of
theoriginalsampleor14,279individuals.
In two validation studies, one involving a
review of medical records and the other
assessing A1C percentages, the self-
reported diagnoses were conﬁrmed for
98% of those reporting diabetes (16).
Statistical analysis
Data were analyzed using means, fre-
quencies, and cross-tabulations to calcu-
late descriptive statistics. The main study
hypothesis was tested using binary logis-
ticregressionanalysis.Antidepressantuse
was coded as absent  0 and present  1
andservedasthedependentvariable.The
model was built in three steps. In step 1,
sex,age,insurancestatus,income,educa-
tion, BMI, smoking status, and alcohol
consumption were entered. In step 2,
level of depressive symptoms (no depres-
sive symptoms, mild depressive symp-
toms, moderate depressive symptoms, or
severe depressive symptoms) was en-
tered. In the ﬁnal step, race was coded
into three categories (whites, African
Americans, and others/mixed race) and
was entered into the regression model,
with whites used as the reference group
for calculating odds ratios (ORs). In the
same model, two-way interactions be-
tween race and the other predictor vari-
ables were also examined. This analytic
strategy tested whether rates of antide-
pressant use differed for African Ameri-
cans and others/mixed race relative to
whitesaftercontrollingforsex,age,insur-
ance status, income, education, BMI,
smoking status, alcohol consumption,
and level of depressive symptoms. All
analyses were done using SPSS (version
17.0; SPSS, Chicago, IL).
RESULTS
Description of the sample
The mean  SD age of the sample with
diabetes was 54.5  9.0, with African
Americans being slightly but signiﬁcantly
younger (P  0.0001) than whites (54.2
vs. 55.4 years). Table 1 provides a de-
scription of the 14,279 participants who
reported a diabetes diagnosis stratiﬁed by
race. Level of income reported in this
sample was very low, with 61% of
each race/ethnicity subgroup reporting
$15,000 per year in family income.
There were signiﬁcant racial differences
in the crude (i.e., unadjusted) demo-
graphic variables. Speciﬁcally, insurance
status, income, education, BMI, smoking
status, alcohol consumption, depressive
symptoms, and antidepressant use dif-
fered by race. African Americans were
more likely to report having health insur-
ance, incomes of $15,000, dropping
out of high school, lower BMI levels,
never having smoked, and consuming
more alcohol on a daily basis than whites
or others/mixed race. African Americans
were more likely to have no depressive
symptoms, whereas whites and others/
mixedraceweremorelikelytohavemod-
erate and severe depressive symptoms.
Finally, among participants reporting di-
abetes, 17.4% of African Americans re-
ported using antidepressant medications
compared with 39.0% of whites and
31.3% of individuals of other/mixed race.
Disparities in antidepressant use
Figure 1 presents a bar graph of the rates
of antidepressant use stratiﬁed by race.
There were disparities in antidepressant
use at all levels of depressive symptoms.
Whites and others/mixed race were more
likelytoreportusingantidepressantsthan
African Americans, regardless of the se-
verity of depressive symptoms.
Table 2 presents the results (ORs and
95% conﬁdence limits) of the logistic re-
gression analysis predicting antidepres-
sant use. Sex and health insurance status
were strong predictors of antidepressant
use, with women and insured individuals
being approximately twice as likely to be
taking antidepressants as men and unin-
sured individuals. Usage tended to de-
crease with advancing age and increasing
income but rose with education and
(slightly) with increasing BMI. Use of an-
tidepressant medications was also posi-
tively associated with smoking, with
former smokers being 1.21 times and
current smokers being 1.46 times more
likely to report antidepressant use than
participants who had never smoked, but
inversely associated with alcohol con-
sumption.Asexpected,useofantidepres-
sant medications was strongly associated
with the level of depressive symptoms.
Participants with severe symptoms were
6.55 times more likely to be taking anti-
Osborn and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 1051depressants than those with the lowest
level of depressive symptoms.
After controlling for these variables,
race was signiﬁcantly associated with an-
tidepressant use (P  0.0001). African
Americans were 0.32 times as likely and
others/mixed race were 0.63 times as
likely to be taking antidepressants than
whites. There were signiﬁcant interac-
tions for race and income (P  0.004),
race and smoking status (P  0.001), and
race and level of depressive symptoms
(P  0.009). An examination of these in-
teractionsshowedthatthedirectionofthe
effect was always consistent, with only a
modest change in the magnitude of the
effect across the various strata.
CONCLUSIONS — We investigated
the relationship between racial status and
antidepressant use in a large low-income
cohort of individuals with diabetes. Al-
though rates of antidepressant use in-
creased as levels of depressive symptoms
increased, a large number of individuals
with moderate and severe depressive
symptomswerenotbeingtreatedwithan-
tidepressant medication. There was a ra-
cial disparity in the use of antidepressants
at all levels of depressive symptoms. After
adjustment for confounders, for every 10
white participants only 3 African Ameri-
can participants were likely to receive an-
tidepressant medications. The prevalence
of antidepressant use was consistently
lowest for African Americans, even after
controllingforfactorsthatinteractedwith
racial status (e.g., income, smoking, and
severity of depressive symptoms).
The present study was conducted
among a diverse sample of adults receiv-
ing care from CHCs in the southeastern
U.S. Two other studies performed in
other regions of the U.S. also reported ra-
cial disparities in antidepressant medica-
tion use among persons with diabetes
(17,18). However, to our knowledge, our
studyistheﬁrsttoshowthisdisparityina
large low-income cohort of older adults
with diabetes and depressive symptoms.
Although socioeconomic status has been
an important determinant of many health
disparities (19), socioeconomic status
measured by self-reported household in-
come and education was associated with
antidepressant use in this study, but the
patterns were conﬂicting, with lower in-
come and higher education being associ-
ated with greater antidepressant use. The
disparity between African Americans and
whites in this sample is unlikely to be ex-
plained by differences in income or edu-
cation, as the difference persisted after
adjustment for these factors.
The reasons for a disparity in antide-
pressant use are not easily apparent and
probably represent a combination of fac-
tors including the recognition and diag-
nosis of depression in African Americans,
as well as access and attitudes toward an-
tidepressant medication in this popula-
tion. In some primary care settings,
providers recognize depression and rec-
ommendtreatmentforAfricanAmericans
Table1—Characteristicsof14,279participantsintheSCCSreportingadiagnosisofdiabetes
Variable and categories
White only
African American
only
Others/mixed
race
Frequency % Frequency % Frequency %
n 3,552 10,164 563
Sex (P  0.057)
Male 1,136 32.0 3,419 33.6 205 36.4
Female 2,416 68.0 6,745 66.4 358 63.6
Age (P  0.0001)
40–49 years 1,072 30.2 3,469 34.1 176 31.3
50–59 years 1,304 36.7 3,954 38.9 235 41.7
60–69 years 919 25.9 2,046 20.1 119 21.1
70–79 years 257 7.2 695 6.8 33 5.9
Insured (P  0.001)
Yes 2,246 63.2 6,771 66.6 365 64.8
No 1,306 36.8 3,393 33.4 198 35.2
Income (P  0.0001)
$15,000 2,241 63.1 6,673 65.7 343 60.9
$15,000–$24,999 720 20.3 2,165 21.3 127 22.6
$25,000–$49,999 416 11.7 1,026 10.1 62 11.0
$50,000 175 4.9 300 3.0 31 5.5
Education (P  0.0001)
Less than high school 1,188 33.4 3,936 38.7 188 33.4
High school or GED 1,415 39.8 3,826 37.6 166 29.5
Some college or votech school 636 17.9 1,650 16.2 147 26.1
Graduated from college 229 6.4 527 5.2 43 7.6
Graduate or professional school 84 2.4 225 2.2 19 3.4
BMI category (P  0.0001)
Underweight (18.5) 45 1.3 149 1.5 5 0.9
Normal (18.5–24.9) 300 8.4 1,031 10.1 55 9.8
Overweight (25–29.9) 743 20.9 2,415 23.8 136 24.2
Obese-I (30–34.9) 934 26.3 2,665 26.2 150 26.6
Obese-II (35–39.9) 700 19.7 1,920 18.9 109 19.4
Obese-III (40) 830 23.4 1,984 19.5 108 19.2
Smoking status (P  0.0001)
Never 1,286 36.2 4,368 43.0 183 32.5
Former smoker 1,160 32.7 2,704 26.6 197 35.0
Current smoker 1,106 31.1 3,092 30.4 183 32.5
Alcohol consumption (P  0.0001)
Never 2,448 68.9 6,339 62.4 356 63.2
1 drink/day 909 25.6 2,577 25.4 156 27.7
1–3 drinks/day 108 3.0 742 7.3 32 5.7
4 drinks/day 87 2.4 506 5.0 19 3.4
Depressive symptoms (P  0.0001)
None 1,764 49.7 5,785 56.9 264 46.9
Mild 808 22.7 2,502 24.6 142 25.2
Moderate 551 15.5 1,191 11.7 89 15.8
Severe 429 12.1 686 6.7 68 12.1
Antidepressant (P  0.0001)
Present 1,385 39.0 1,770 17.4 176 31.3
Absent 2,167 61.0 8,394 82.6 387 68.7

2 test for categorical variables. GED, general education degree. Votech, vocational/technical.
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However, even when depression is recog-
nized, African Americans were less likely
to take antidepressant medications than
whites. Attitudes toward medications,
particularly antidepressant medication,
may contribute to this disparity. African
Americans are less likely than whites to
accept antidepressant treatment (20) and
have been shown to prefer counseling
over antidepressant medication (21). Af-
rican Americans may also use spirituality
and religion as a coping mechanism more
frequently than whites.
There are several study limitations to
acknowledge. First, because this is a
cross-sectional study, inferences regard-
ing causal relationships cannot be made.
Second, diagnosis of diabetes was self-
reportedandnotbasedonchartreviewor
biological testing. In a separate validation
study, 124 medical records of SCCS par-
ticipants reporting a prior diagnosis of di-
abeteswerereviewed,and98%oftheself-
reports were validated based on criteria
including ICD-9 codes, physician notes
or prescriptions, and/or A1C or blood
glucose measurements from the medical
records (16). Third, antidepressant use
may have been differentially reported be-
cause of differences in beliefs, attitudes,
and preferences for treatment (20,21).
Fourth, unmeasured differences in pre-
senting depression-related complaints
wereunaccountedfor,aswerephysicians’
treatmentpriorities.Providersmaybeless
likely to discuss depression treatment
with African Americans who are often
sickerwhenseekingcareandpresentwith
more somatic attributions (22). Finally,
although the CES-D has been validated in
various populations, including multieth-
nic groups with diabetes (23), it may not
be psychometrically equivalent across
race-ethnicity or immigrant generations
(24) and has demonstrated false-positive
rates in low-income CHC settings. In one
study, the standard cutoff for major de-
pressive disorder yielded a sensitivity of
0.95 and speciﬁcity of 0.70, but more
than two-thirds of those who screened
positive did not actually meet the criteria
for major depressive disorder (25). Thus,
itispossiblethatdepressionwouldnotbe
diagnosed in some study participants
who reported mild and moderate depres-
sive symptoms or they would not be con-
sidered good candidates for treatment
after a clinician conducted a careful diag-
nostic interview.
Despite these limitations, our ﬁnd-
ings suggest a sizable racial disparity in
antidepressant use in a large, low-income
cohort of individuals with diabetes and
depressivesymptoms.Giventhisisapop-
ulationwithlargenumbersofpeoplewith
diabetes and with limited access to health
careservices,ourﬁndingsprovideimpor-
tant evidence of the need for appropriate
management of depression as part of reg-
ular diabetes care. Treatment for depres-
sion in individuals with diabetes may
improve glycemic control, overall func-
tioning, and quality of life (2), thereby
reducing one’s risk of adverse health out-
comes associated with untreated depres-
sion. Conversely, untreated depression
might contribute to racial disparities in
diabetes outcomes, complications, and
premature death. The mechanisms un-
derlying the association between racial
status and antidepressant use is likely to
be multifactorial. Prospective studies are
needed to more closely examine the asso-
ciation between racial status and depres-
sion treatment in low-income, ethnic
minority, adults with diabetes.
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